HRSA approves 340B rebate models to hospitals’ chagrin
Drugs that will be subject to rebates in 340B next year include Bristol Myers Squibb’s Eliquis, Johnson & Johnson’s Stelara and Novo Nordisk’s Novolog.
New CBO report confirms 340B’s ballooning costs. Congress must act.
Former Congressional Budget Office Director Dan Crippen argues the 340B discount program is overdue for reform.
Few health systems report significant ROI from virtual care: survey
Fewer than 30% of health system leaders said they earned significant return on investment from virtual care offerings, according to the report by Sage Growth Partners.
Teladoc expands insurance coverage at mental health unit BetterHelp
Executives expect insurance coverage availability will be “largely national” by the end of 2026. The initiative is important for Teladoc to turn around financial performance for the segment, which has seen earnings and revenue decline.
Cigna’s 2026 pharmacy profits could be dampened by transition to rebate-free model
Overall, Cigna expects earnings to grow next year after posting a solid third quarter. But investments in a new PBM model and discounted contracts for some big clients could lower Express Scripts’ profitability, executives said.
Summa Health CEO to step down at end of 2025
Dr. Cliff Deveny announced the transition less than a month after General Catalyst finalized its $515 million acquisition of Summa.
FDA, aiming to lower drug costs, moves to speed approval of biosimilars
The agency will no longer require studies comparing copycat biologics to their branded counterparts, which could help developers bring them to market more quickly and cheaply.
Centene posts $6.6B loss on massive value writedown
The goodwill impairment charge is meant to realign Centene’s value on its own books with its value in the market, which has plummeted this year. Still, Centene upped its earnings outlook for 2025.
Tenet pledges more money for high-acuity growth in 2025
The hospital operator will invest more in organic hospital growth and high-acuity service lines as it sees strong demand for services.
CVS hikes 2025 guidance despite goodwill impairment charge on healthcare delivery
The healthcare giant beat Wall Street expectations in the third quarter, but reported a net loss after recording a $5.7 billion charge linked primarily to decelerating clinic growth at Oak Street Health.